HYBRID EVENT: You can participate in person at Valencia, Spain or Virtually from your home or work.
Guo Wei He, Speaker at Chemical Engineering Conferences
TEDA International Cardiovascular Hospital, Tianjin University, China
Title : Role of lysine propionylation of human right atrium and ALDH6A1-NADH pathway in new-onset atrial fibrillation after coronary surgery

Abstract:

Lysine propionylation modification (Kpr) plays an important role in the pathogenesis of several cardiovascular diseases, but the role of Kpr in postoperative atrial fibrillation (POAF) is unclear. Here, we established an atlas of proteomics and propionylation proteomics in the atrial appendage tissues from 28 CABG patients, exploring the role of Kpr proteins in the occurrence of POAF. The Kpr of ALDH6A1 was most significantly increased on Lys113 (2.25 folds). The activity of ALDH6A1 increased due to higher binding energy of propionylated ALDH6A1 and NAD+, causing an increase in NADH levels in cells and triggering abnormal energy metabolism. Furthermore, the increase in NADH levels triggered the accumulation of reactive oxygen species, which may cause oxidative stress, resulting in the development of AF. This study reveals the important role of ALDH6A1-NADH pathway in POAF, and provides new insights for exploring the pathogenesis of POAF in CABG.

Biography:

Professor Guo-Wei HE, MD, PhD, DSc, is Distinguished Professor of Tianjin University, China and Academician (Foreign Correspondence Member) at The National Academy of Medicine, France (2019-). Professor He is Vice President & Senior Cardiac Surgeon at TEDA International Cardiovascular Hospital, Tianjin University and Director of Institute for Cardiovasc Diseases, Tianjin University & Chinese Academy of Medical Sciences. He also holds Clinical Professor of Surgery at Oregon Health & Science University, Portland, OR, USA (2003-). In addition, Professor He is Director, Branch Center for National Clinical Research Center for Cardiovascular Disease and Director of Tianjin Key Laboratory for Molecular Regulation and Translational Medicine of Cardiovascular Diseases. He obtained Doctor of Science (2003) and Ph. D.(1989) from Monash University, Melbourne, Australia.

Professor He was Chair Professor of Cardiothoracic Surgery, University of Hong Kong, 1995-2000 and Research Chair Professor, Chinese University of Hong Kong (2000-2009). Professor He was Director of Cardiovasc Res Lab, St, Vincent Hospital, Portland, OR, U.S.A. (1994-2012). Professor He is an active cardiac surgeon and he performed about 8,000 open heart operations. Notably, he is the first surgeon performing radial artery plus internal mammary artery in CABG at University of Hong Kong in Asia (1995) and is well known for “He Classification” and “He solutions” for CABG grafts. Apart from clinical practice, he is an active research on basic science at the molecular (genetic and protein) level and obtained more than 80 research grants and awards such as First Class Award, Tianjin Municipal Natural Science Award (2012), First Class Award, Prize of Science & Technology, The China Medicine Education Association (2021), exec.  Professor He has supervised PhD students and postdoc for more than 30 years.

He published 439 articles/reports in SCI-index international journals, including Circulation (IF: 39.918) 5 articles,Nature Reviews Cardiology(IF: 41.7), Signal Transduction and Targeted Therapy(IF:38.104), Lancet (IF:168.9), Lancet Digit Health(IF:36.615)exec.

He ranks the top 0.05% of all scholars worldwide (ScholarGPS), World's Top 2% Scientists (2019-2024) by Stanford University and H-index of world top 1%. Professor He ranks world’s top 1% in Medicine, Chemistry, Genetics and Molecular Biology; He is Highly-cited Chinese Scholar in Clinical Medicine (Elsevier 2024).

Watsapp